Mesoblast Limited have exclusively licensed patented technology originally developed at Harvard Medical School which can be used to modify mesenchymal lineage adult stem cells (MLCs).
This process of ex vivo fucosylation, which adds fucose to the cell’s surface receptors, allows MLCs to be recognized and bound by cells lining the blood vessels of inflamed tissues, giving the MLCs enhanced homing properties.
Preclinical studies have demonstrated that modified MLCs are able to successfully induce a durable reversal of Type 1 diabetes. The enhanced targeting technology was able to increase the number of MLCs that could reach the inflamed pancreas in autoimmune diabetic mice by three-fold.
“The hypothesis was that inflammation that destroys pancreatic islet cells could be controlled by selectively targeting the pancreas with anti-inflammatory mesenchymal lineage cells. The realization was that this new clinical approach essentially cured mice of Type 1 diabetes,” explained Robert Sackstein, Professor of Medicine at Harvard Medical School.
Source: New Mesoblast Cell Targeting Technology Shows Potential to Induce Durable Reversal of Type 1 Diabetes; Press Release